It's never fun for a company when it's considering winding down.
Of course the company can continue, but when the market valuation is lower than breakup value, it may be time to consider ending it.
If the company continues and is not successful, it may be in a difficult spot to raise funds. The market is not particularly strong at the moment and many offerings have been priced 20-30% lower than current prices.
Not to say that they need to raise cash now, but if the outlook isn't great, it might be in the best interest of shareholders to wind down the company.
The big issue is that doubt has been placed on VS-6063 and it's efficacy. I am a trader, so my motives may not be as altruistic as others. But when a significant amount of your pipeline is in question, things don't look the best.
Recent VSTM News
- Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer • Business Wire • 04/18/2024 08:05:00 PM
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/04/2024 11:30:00 AM
- Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer • Business Wire • 03/18/2024 11:00:00 AM
- Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates • Business Wire • 03/14/2024 08:05:00 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 03/11/2024 09:07:54 PM
- Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs • Business Wire • 03/11/2024 11:30:00 AM
- Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer • Business Wire • 03/05/2024 10:27:00 PM
- Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024 • Business Wire • 03/05/2024 09:30:00 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 02/08/2024 09:22:55 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/02/2024 02:49:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 09:01:10 PM
- Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers • Business Wire • 01/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 12:54:28 PM
- Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) • Business Wire • 01/18/2024 09:00:00 PM
- Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference • Business Wire • 01/11/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 09:03:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:02:35 PM
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/05/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 09:04:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 09:01:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 09:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 09:00:56 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/19/2023 09:01:19 PM
- Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics • Business Wire • 12/18/2023 12:00:00 PM
- Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer • Business Wire • 12/13/2023 12:00:00 PM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM